Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-Controlled, Phase III Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 2) Study

NCT01322347 is registered in ClinicalTrials.gov with Rockwell Medical Technologies, Inc. as lead sponsor.

NCT NCT01322347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01322347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-Controlled, Phase III Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 2) Study
Lead sponsor
Rockwell Medical Technologies, Inc.
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2011
Completion date
February 28, 2014
Enrollment
294 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

renal failure chronic requiring hemodialysis